Please ensure Javascript is enabled for purposes of website accessibility

Sanofi Grows Revenue by 6.8% in Fourth Quarter Boosted by Dupixent

By Brian Orelli, PhD - Feb 6, 2020 at 5:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sometimes slow and steady wins the race.

Sanofi (SNY -7.11%) saw sales increase 6.8% in the fourth quarter to €9.608 billion ($10.55 billion). Some of the increase was due to a stronger Euro; at constant exchange rates, sales were up a more modest 4.7% year over year.

On the bottom line, Sanofi lost €10 million as there was an impairment charge associated with its hemophilia treatment Eloctate that's struggling in the U.S. due to added competition. But on an adjusted basis, which Sanofi calls its "business net income," the French pharmaceutical company made €1.684 billion, up 18.4% year over year.

The results drove shares of Sanofi up 4.7% on Thursday.

Dupixent was the biggest contributor to growth with sales more than doubling to €679 million. The drug, which Sanofi sells with Regeneron Pharmaceuticals (REGN 3.11%), is approved in the U.S. to treat eczema, asthma and nasal polyposis.

Pills on $100 bills

Image source: Getty Images.

Sales of vaccines increased 22%, boosted by early shipments of influenza vaccine in the U.S.

Revenue from consumer healthcare was down 5.2% compared to the year-ago quarter because of the recall of heartburn medication Zantac as the Food and Drug Administration worried about the potential for unacceptable levels of N-nitrosodimethylamine (NDMA). Sanofi also divested some products in the category, which hurt the year-over-year comparison.

The primary care business unit saw sales fall 8.7% due to lower sales of diabetes products as well as its older medications, fondly referred to as "established products," which fell 9.2% and 6.3%, respectively

This year, management thinks adjusted earnings per share (business EPS) will grow about 5% at constant exchange rates. If currency exchange rates stay where they were for January, reported earnings per share will be one percentage point higher.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$45.20 (-7.11%) $-3.46
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$641.49 (3.11%) $19.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.